Fluocinonide

CHEMBL1501 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
494.5 g/mol
LogP
3.2
Phase
4

This high-potency topical corticosteroid is used to relieve the inflammation, itching, and scaling associated with skin conditions such as psoriasis, eczema, and contact dermatitis. It should be applied sparingly and for limited periods to minimize the risk of skin thinning and other side effects.

Moleküler Ağırlık

494,5000 g/mol

LogP

3,20

TPSA

99,10 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C

InChI

InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1

Molecular Formula

C26H32F2O7

HBD / HBA

1 / 9

Döndürülebilir Bağlar

4

Ağır Atomlar

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This high-potency topical corticosteroid is used to relieve the inflammation, itching, and scaling associated with skin conditions such as psoriasis, eczema, and contact dermatitis. It should be applied sparingly and for limited periods to minimize the risk of skin thinning and other side effects.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Fluocinonide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1501. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9642. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.